ATE380176T1 - Benzanilide als öffner des kaliumkanals - Google Patents

Benzanilide als öffner des kaliumkanals

Info

Publication number
ATE380176T1
ATE380176T1 AT00955367T AT00955367T ATE380176T1 AT E380176 T1 ATE380176 T1 AT E380176T1 AT 00955367 T AT00955367 T AT 00955367T AT 00955367 T AT00955367 T AT 00955367T AT E380176 T1 ATE380176 T1 AT E380176T1
Authority
AT
Austria
Prior art keywords
potassium channel
benzanilide
opener
benzanilides
voltage
Prior art date
Application number
AT00955367T
Other languages
English (en)
Inventor
Grant Mcnaughton-Smith
Michael Gross
Alan Wickenden
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Application granted granted Critical
Publication of ATE380176T1 publication Critical patent/ATE380176T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AT00955367T 1999-08-04 2000-08-04 Benzanilide als öffner des kaliumkanals ATE380176T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14722199P 1999-08-04 1999-08-04

Publications (1)

Publication Number Publication Date
ATE380176T1 true ATE380176T1 (de) 2007-12-15

Family

ID=22520715

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955367T ATE380176T1 (de) 1999-08-04 2000-08-04 Benzanilide als öffner des kaliumkanals

Country Status (10)

Country Link
US (4) US6372767B1 (de)
EP (1) EP1208085B1 (de)
JP (1) JP2003506387A (de)
AT (1) ATE380176T1 (de)
AU (1) AU779034B2 (de)
CA (1) CA2378241A1 (de)
DE (2) DE60037321T4 (de)
NZ (1) NZ516610A (de)
WO (1) WO2001010380A2 (de)
ZA (1) ZA200200502B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1200086A4 (de) * 1999-08-04 2009-05-27 Icagen Inc Methoden zur behandlung oder vorbeugung von schmerzen und angstzuständen
AU2002238023B2 (en) * 1999-08-04 2008-03-13 Icagen, Inc Pyridine-substituted benzanilides as potassium ion channel openers
ATE380176T1 (de) 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
EP1363624A2 (de) * 2001-02-20 2003-11-26 Bristol-Myers Squibb Company Fluoroxindol-derivate als modulatoren der kcnq-kalium-kanälen
HUP0401750A2 (hu) 2001-05-31 2004-12-28 Bristol-Myers Squibb Company Cinnamidszármazékok mint KCNQ káliumcsatorna-modulátorok és ezeket tartalmazó gyógyszerkészítmények
US7205307B2 (en) * 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
DE60316161T2 (de) * 2002-06-25 2008-06-19 Serono Genetics Institute S.A. Neue kcnq-polypeptide und deren verwendung bei der diagnose von geisteskrankheiten
US7442519B2 (en) * 2002-06-25 2008-10-28 Serono Genetics Institute, S.A. KCNQ2-15 potassium channel
US7087609B2 (en) 2002-11-22 2006-08-08 Bristol-Myers Squibb Company 3-(pyridinyl-piperazin-1-yl)-phenylethyl amides as potassium channel openers
US7045551B2 (en) 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
EP1581498A2 (de) 2002-11-22 2005-10-05 Bristol-Myers Squibb Company Pyridinyl-, pyrimidinyl-und pyrazinylamide als kaliumkanalöffner
WO2004047738A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Arylcyclopropylcarboxylic amides as potassium channel openers
AU2003294442A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
EP1603858A2 (de) * 2003-03-11 2005-12-14 NeuroSearch A/S Kncq-kanal-modulatoren und ihre pharmazeutische verwendung
MXPA06003951A (es) 2003-10-07 2006-06-27 Renovis Inc Derivados de amida como ligandos del canal de ion y composiciones farmaceuticas y sus metodos de uso.
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
EP1782812A1 (de) * 2004-06-23 2007-05-09 Neurotec Pharma, S.L. Verbindungen zur behandlung von entzündungen des zentralen nervensystems
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
EP1838690A2 (de) * 2004-12-21 2007-10-03 Devgen N.V. Auf den kv-4-ionenkanal wirkende verbindungen
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
UA92340C2 (en) * 2005-03-03 2010-10-25 Х. Луннбек А/С Substituted pyridine derivatives
EP1861394A1 (de) * 2005-03-03 2007-12-05 H.Lundbeck A/S Substituierte pyridinderivate
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
CN101578259A (zh) * 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
JP2010520875A (ja) 2007-03-09 2010-06-17 レノビス， インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
AR070513A1 (es) * 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
CN101765425A (zh) * 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CA2751534A1 (en) * 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
CA2805932A1 (en) 2010-08-27 2012-03-01 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
MX342459B (es) 2010-08-27 2016-09-29 Grünenthal Gmbh * 2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas sustituidas, como moduladores de kcnq2/3.
RU2595894C2 (ru) 2010-08-27 2016-08-27 Грюненталь Гмбх Замещенные 2-окси-хинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
CA2807886A1 (en) 2010-09-01 2012-03-08 Gruenenthal Gmbh Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
WO2015143654A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
WO2020201773A1 (en) * 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2891958A (en) * 1958-05-29 1959-06-23 Reilly Tar & Chem Corp Certain alkyl n-pyridylthiopicolinamides and alkyl n-pyridylthiosonicotinamides and process
US3835145A (en) * 1972-09-11 1974-09-10 Sterling Drug Inc 2- and 3-pyridylisothiocyanates
JPS57131719A (en) * 1981-02-10 1982-08-14 Chugai Pharmaceut Co Ltd Blood sugar level lowering agent
JPS57206661A (en) * 1981-06-15 1982-12-18 Chugai Pharmaceut Co Ltd Acetaminobenzamide derivative
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
DE3305569A1 (de) * 1983-02-18 1984-08-23 Bayer Ag, 5090 Leverkusen Biscarboxamide zur bekaempfung von erkrankungen sowie verfahren zu ihrer herstellung
JPS59175467A (ja) * 1983-03-25 1984-10-04 Chugai Pharmaceut Co Ltd ウレイドベンズアミド誘導体
JPS59181257A (ja) 1983-03-31 1984-10-15 Chugai Pharmaceut Co Ltd ウレイドベンズアミド誘導体
DE3804346A1 (de) 1988-02-12 1989-08-24 Boehringer Mannheim Gmbh Tert.-butylphenyl-pyridyl-amide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
JPH08176113A (ja) * 1993-11-12 1996-07-09 Dainippon Pharmaceut Co Ltd ２−スルフィニルニコチンアミド誘導体及びその中間体並びにそれを有効成分とする消化性潰瘍治療薬
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
JPH10259176A (ja) * 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
AU6422098A (en) 1997-03-24 1998-10-20 Kyowa Hakko Kogyo Co. Ltd. Benzene derivatives
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
JP2001510827A (ja) 1997-07-25 2001-08-07 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 置換６−フェニルフェナントリジン
ATE380176T1 (de) 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
CA2384291A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
AU2001231143A1 (en) 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
UA76512C2 (en) 2001-09-04 2006-08-15 Boehringer Ingelheim Pharma Dihydropteridinones, a method for producing thereof and use thereof as medicament

Also Published As

Publication number Publication date
AU779034B2 (en) 2005-01-06
WO2001010380A2 (en) 2001-02-15
US6989398B2 (en) 2006-01-24
US6737422B2 (en) 2004-05-18
EP1208085B1 (de) 2007-12-05
US20020052393A1 (en) 2002-05-02
EP1208085A2 (de) 2002-05-29
CA2378241A1 (en) 2001-02-15
NZ516610A (en) 2004-05-28
JP2003506387A (ja) 2003-02-18
DE60037321D1 (de) 2008-01-17
DE60037321T2 (de) 2008-11-27
US20020091122A1 (en) 2002-07-11
AU6758500A (en) 2001-03-05
US20040157829A1 (en) 2004-08-12
US6605725B2 (en) 2003-08-12
EP1208085A4 (de) 2003-05-02
DE60037321T4 (de) 2010-01-07
US6372767B1 (en) 2002-04-16
ZA200200502B (en) 2003-04-30
WO2001010380A3 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
ATE380176T1 (de) Benzanilide als öffner des kaliumkanals
DK1847611T3 (da) Rhamnose-inducerbart ekspressionssystem
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
IL211367A0 (en) An antibody, a fragment thereof, a method of preparing the same and a use of the antibody
GB2390091B (en) Bisarylamines as potassium channel openers
MY136097A (en) Methods for treating osteoarthritis using an estrogen agonist/antagonist
IL139080A0 (en) Btx inhibitors and methods for their indentification and use
MXPA05014016A (es) Proteinas portadoras para vacunas.
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
GB2387696A (en) Real-time odds-based gaming
EP1363884A4 (de) Pyridinsubstituierte benzanilide als kaliumionenkanalöffner
EP1545453A4 (de) Verfahren und reagenzien zur behandlung von infektionen mit clostridium difficile und damit zusammenhängende erkrankungen
BRPI0414267A (pt) polipeptìdeos de campilobacter e métodos de uso
GB2377295A (en) Conversational dealing system
TW200510398A (en) Novel compounds
FI20021224A7 (fi) Parannettu menetelmä päätelaitekeskustelun toteuttamiseksi ja menetelmää hyödyntävä päätelaite
WO2005087932A3 (en) Vectors for directional cloning
AU148415S (en) Bottle
PL380665A1 (pl) Farmaceutyczne kompozycje
MXPA02007173A (es) Compuestos calciliticos.
MXPA05005574A (es) Compuestos calciliticos.
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
SG140447A1 (en) Method of forming a micro-rotating device, and a micro-rotating device produced by the method
MXPA05012562A (es) Combinaciones antiartritis.
EP1383511A4 (de) Kalzilytische verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties